Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRP-180 for narcolepsy
ACTRN12625000879460Phase 2Not yet recruiting
- Sponsor
- Bioron Pharma
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BRP-180 in narcolepsy (3 arms), sponsored by Bioron Pharma. Primary endpoint: Change in wakefulness. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
BRP-180
03
Conditions
narcolepsy
Beyond the preview
Go deeper on ACTRN12625000879460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000879460.